EG19814A - A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose - Google Patents

A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Info

Publication number
EG19814A
EG19814A EG41291A EG41291A EG19814A EG 19814 A EG19814 A EG 19814A EG 41291 A EG41291 A EG 41291A EG 41291 A EG41291 A EG 41291A EG 19814 A EG19814 A EG 19814A
Authority
EG
Egypt
Prior art keywords
flupirtine
thr
agent
preparation
active substance
Prior art date
Application number
EG41291A
Other languages
English (en)
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Application granted granted Critical
Publication of EG19814A publication Critical patent/EG19814A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
EG41291A 1990-07-14 1991-07-09 A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose EG19814A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (instruction) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
EG19814A true EG19814A (en) 1996-02-29

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
EG41291A EG19814A (en) 1990-07-14 1991-07-09 A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Country Status (30)

Country Link
US (2) US5162346A (instruction)
EP (2) EP0467164B1 (instruction)
KR (1) KR0182811B1 (instruction)
CN (1) CN1070700C (instruction)
AT (2) ATE206919T1 (instruction)
AU (1) AU634073B2 (instruction)
CA (1) CA2046943C (instruction)
CZ (1) CZ280879B6 (instruction)
DE (3) DE59109222D1 (instruction)
DK (2) DK0659410T3 (instruction)
EG (1) EG19814A (instruction)
ES (2) ES2082887T3 (instruction)
GR (1) GR3019179T3 (instruction)
HR (1) HRP920667B1 (instruction)
HU (1) HU206973B (instruction)
IE (1) IE74688B1 (instruction)
IL (1) IL98810A (instruction)
IN (1) IN172468B (instruction)
LT (1) LT3593B (instruction)
LV (1) LV10048B (instruction)
MC (1) MC2272A1 (instruction)
MX (1) MX9100160A (instruction)
NO (1) NO912758L (instruction)
NZ (1) NZ238940A (instruction)
PT (1) PT98291B (instruction)
RO (1) RO108220B1 (instruction)
RU (1) RU2070408C1 (instruction)
SI (1) SI9111227B (instruction)
SK (1) SK279567B6 (instruction)
ZA (1) ZA915466B (instruction)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
SK1712002A3 (en) * 1999-08-03 2003-03-04 Awd Pharma Gmbh & Co Kg Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
CA2650853A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
JP5419691B2 (ja) * 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
NZ787838A (en) 2019-11-08 2025-08-29 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
CA3207191A1 (en) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Also Published As

Publication number Publication date
LT3593B (en) 1995-12-27
EP0659410B1 (de) 2001-10-17
EP0467164A3 (en) 1992-04-15
IE74688B1 (en) 1997-07-30
PT98291B (pt) 1999-01-29
KR0182811B1 (ko) 1999-05-01
HRP920667A2 (en) 1996-10-31
LTIP919A (en) 1995-03-27
EP0467164B1 (de) 1996-01-31
DE4122166A1 (de) 1992-01-16
EP0467164A2 (de) 1992-01-22
ES2164111T3 (es) 2002-02-16
ES2082887T3 (es) 1996-04-01
LV10048A (lv) 1994-05-10
RO108220B1 (ro) 1994-03-31
MX9100160A (es) 1992-02-28
EP0659410A3 (de) 1995-10-25
ATE133564T1 (de) 1996-02-15
HRP920667B1 (en) 1998-06-30
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
IE912451A1 (en) 1992-01-15
HU912359D0 (en) 1991-12-30
HU206973B (en) 1993-03-01
GR3019179T3 (en) 1996-06-30
AU634073B2 (en) 1993-02-11
AU8040391A (en) 1992-01-16
CN1058716A (zh) 1992-02-19
CA2046943C (en) 1996-03-12
ATE206919T1 (de) 2001-11-15
MC2272A1 (fr) 1993-06-23
SI9111227A (en) 1995-06-30
CZ280879B6 (cs) 1996-04-17
US5284861A (en) 1994-02-08
DE59109222D1 (de) 2001-11-22
EP0659410A2 (de) 1995-06-28
CN1070700C (zh) 2001-09-12
SI9111227B (sl) 2000-12-31
PT98291A (pt) 1992-05-29
CA2046943A1 (en) 1992-01-15
SK279567B6 (sk) 1999-01-11
DK0659410T3 (da) 2001-12-27
CS210191A3 (en) 1992-02-19
RU2070408C1 (ru) 1996-12-20
NO912758L (no) 1992-01-15
LV10048B (en) 1995-06-20
IL98810A0 (en) 1992-07-15
DK0467164T3 (da) 1996-03-04
IL98810A (en) 1996-01-19
IN172468B (instruction) 1993-08-14
HUT59313A (en) 1992-05-28
ZA915466B (en) 1992-04-29
DE59107331D1 (de) 1996-03-14
KR920002147A (ko) 1992-02-28
NO912758D0 (no) 1991-07-12

Similar Documents

Publication Publication Date Title
EG19814A (en) A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
EP0331620A3 (en) Agent for the treatment of parkinson's disease
EP0279887A3 (en) Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
MY104521A (en) Treatment of depression.
ZA9010080B (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
NZ222045A (en) From diamides up to tetrapeptides for use as anticanvulsants
EP0872246A4 (en) INNOVATIVE MEDICINE TO REDUCE PAIN AND PROMOTE REMOVAL OF CONCRETE IN UROLITHIASIS
IL89082A0 (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
EP0458537A3 (en) Therapeutic compound for the treatment of bronchitis
EP0436717A4 (en) Method of treatment with medical agents
GR3002925T3 (en) Compound active in cardiovascular therapy
EP0182569A3 (en) Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
IL82279A0 (en) Fumigant method and compositions comprising 2,2-dibromo-3-nitrilopropionamide for treating crops
GEP19971009B (en) Flupirtine in combination with antiparkinsonica against muscle bracing
BG98001U (en) Medicament for the treatment of hyperkeratotic conditions of the skin
ZA923505B (en) Treatment of fatigue syndrome
ZA89574B (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
IE900102L (en) Treatment of skin disorders